PDCD1 and melanoma: In the present study, we found that SPHK1-MTA3 axis-induced PD-L1 expression in melanoma could improve anti-PD-1 therapy in vivo, which indicated that the SPHK1-MTA3 axis might be a potential biomarker for the prediction of the prognosis of advanced melanoma patients.